OPPORTUNITY FOR INNOVATION IN ASPIRIN DELIVERY
Plain aspirin is associated with local GI injury, which can be asymptomatic2
In patients using aspirin for secondary prevention, discontinuation led to a 46% higher rate of cardiovascular events3
There hasn’t been innovation in the mechanism of
aspirin delivery in over 50 years
- CFR — Code of Federal Regulations Title 21. Internal Analgesic, Antipyretic, and Antirhreumatic Drug Products for Over-the-Counter Human Use. Food and Drug Administration; US Dept of Health and Human Services; 2015.
- Cryer B, Mahaffey KW. Gastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatment. J Multidiscip Healthc. 2014;7:137-146.
- Sundström J, Hedberg J, Thuresson M, Aarskog P, Johannesen KM, Oldgren J. Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study. Circulation. 2017;136(13):1183-1192.